Hiberix (Haemophilus Type B Conjugate Vaccine (Tetanus Toxoid Conjugate))

Hiberix is indicated for active immunization against Haemophilus influenzae type b (Hib) and is incorporated into pediatric vaccination programs to reduce the risk of invasive Hib disease.

• Primary prevention of Hib meningitis, pneumonia, epiglottitis, and septicemia in infants and young children.
• Administration as part of the routine childhood immunisation schedule, typically in a three‑dose series.
• Use in catch‑up vaccination for children who have not completed the primary series.
• Immunisation of travelers to regions where Hib disease remains endemic.
• Co‑administration with other pediatric vaccines (e.g., DTaP, polio) when clinically appropriate.

• Hiberix works by chemically linking the capsular polysaccharide of Haemophilus influenzae type b to tetanus toxoid, forming a conjugate that is recognized by helper T cells. This conjugation converts the normally T‑cell‑independent polysaccharide antigen into a T‑cell‑dependent form, prompting robust B‑cell activation, class‑switching, and the generation of high‑affinity anti‑polyribosylribitol phosphate (PRP) antibodies and immunologic memory that provide long‑lasting protection against Hib infection.

Like other conjugate vaccines, Hiberix may be associated with local and systemic reactions, most of which are mild and self‑limiting.

Common

• Pain, redness, or swelling at the injection site.
• Low‑grade fever (≤38.5 °C) within 24 hours after vaccination.
• Irritability or fussiness in infants.
• Mild fatigue or reduced appetite for a day or two.

Serious

• Severe allergic reaction (anaphylaxis) characterized by hives, airway swelling, or hypotension.
• High‑grade fever (>40 °C) persisting beyond 48 hours.
• Neurologic events such as seizures or encephalopathy (rare).
• Persistent vomiting or severe diarrhoea.

Healthcare professionals should assess individual risk factors before administering Hiberix and observe patients for any immediate reactions.

• Do not administer to persons with a known severe allergy to any vaccine component, including tetanus toxoid.
• Postpone vaccination in individuals with a moderate or severe acute illness until recovery.
• Use caution in patients with a history of seizures or neurologic disorders; monitor after injection.
• Discuss the benefits and risks with pregnant or breastfeeding women, as safety data are limited.
• Ensure proper intramuscular or subcutaneous technique to minimize injection‑site complications.
• Review immunisation records to avoid unnecessary repeat dosing.

Vaccines generally have limited drug‑drug interactions, but certain conditions may affect the safety or efficacy of Hiberix.

Avoid

• Concurrent administration of live bacterial vaccines (e.g., oral typhoid) that could interfere with the immune response to Hiberix.
• Use of high‑dose immunosuppressive therapies (such as systemic corticosteroids or biologics) that may diminish the vaccine‑induced antibody production.

Use with caution

• Simultaneous receipt of other injectable vaccines; monitor for additive local reactions such as increased redness or swelling.
• Prophylactic antipyretics (acetaminophen or ibuprofen) taken at the time of vaccination may modestly reduce the antibody response; they should be used only for therapeutic relief of symptoms.
• Patients who have received blood products or immunoglobulin therapy within the past three months, as passive antibodies can interfere with the development of active immunity.